DNA mismatch repair (MMR) in leukemogenesis [23] [24] [25] . Mice lacking Msh2, whose product is the key component of both the MutSα and MutSβ complexes that mediate DNA MMR, display a genetic phenotype that closely mimics the spectrum of mutations found in aging human HSCs and in patients with myeloid leukemia (transition mutations and small insertions and deletions) 26, 27 . We therefore generated a mouse model carrying a heterozygous deletion of an upstream enhancer of Spi1 (also called PU.1 here) and a homozygous deletion of Msh2 to evaluate the role of minimal PU.1 reduction in the context of acquired mutations.
RESULTS

Minimal reduction of PU.1 expression leads to AML
To assess the effects of minimal PU.1 inhibition in the context of an elevated number of point mutations, in particular C to T or G to A transitions and small insertions or deletions resembling the mutations acquired in aging human individuals and in patients with AML, we crossed mice with a heterozygous deletion of a regulatory element 14 kb upstream of the transcriptional start site of PU.1 (referred to as 'URE het ' here) 9 with Msh2 −/− mice 28 . URE het Msh2 −/− mice were born at Mendelian frequencies. PU.1 expression in hematopoietic multipotent stem and progenitor cells sorted from URE het mice exhibited a significant (P < 0.05) but very modest reduction of PU.1 expression as compared to wild-type (WT) littermates (37% ± 8% in Lin − Sca-1 + cKit + (LSK) cells, 33% ± 4% in common myeloid progenitor (CMP) cells, and 26% ± 20% in granulocytic-monocytic progenitor (GMP) cells) ( Fig. 1a and Supplementary Fig. 1a,b) . Western blotting confirmed minimal impairment of PU.1 expression at the protein level (36% reduction in myeloid progenitor cells and 21% reduction in mature neutrophils; Supplementary Fig. 1c ). As previously reported 9 , URE − mice showed a much greater reduction in PU.1 levels (97% ± 2% reduction in LSK cells, 92% ± 3% reduction in CMP cells, and 76% ± 5% reduction in GMP cells) ( Fig. 1a and Supplementary Fig. 1a,b) .
In agreement with previous reports, we observed that Msh2 −/− mice developed T cell lymphomas with 100% penetrance and a late onset 29 (Fig. 1b) . Minimal reduction of PU.1 in combination with the Msh2 deficiency had a two-pronged effect: (i) the median survival time was reduced from 7.6 months for URE + Msh2 −/− mice to 4.6 months for URE het Msh2 −/− mice (P = 0.0026; log-rank test), and (ii) the disease phenotype was altered to AML in more than two mice with either AML (n = 18), mixed lineage AML and ALL (n = 10) or T cell lymphoma (n = 11). If not specified otherwise, significance values are indicated as *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test); n.s., not significant. npg thirds of URE het Msh2 −/− mice (Fig. 1c-j) . AML was never observed in URE + Msh2 −/− mice. To exclude the possibility that the observed myeloid phenotype was caused by further inhibition of PU.1 expression or function, we examined expression of known PU.1 target genes in different stem and progenitor cells and found only minimal reduction in their expression levels in URE het Msh2 +/+ mice and no further reduction in their expression levels in URE het Msh2 −/− mice (Supplementary Fig. 1d ). In mice with AML, we also ensured that the PU.1-encoding gene or its regulatory regions had not acquired mutations that further reduced PU.1 activity (the one mouse out of the 20 mice examined in which this was the case was excluded from further analyses) (Supplementary Fig. 1e) .
Macroscopically, URE het Msh2 −/− leukemic mice presented with severe splenomegaly (Fig. 1c) and hepatomegaly (data not shown). Moribund URE het Msh2 −/− AML mice showed elevated white blood cell counts (WBCs) and reduced red blood cell and platelet counts as compared to 4-to 12-week-old preleukemic mice of the same genotype or to age-matched WT animals ( Fig. 1d-f ). We assessed WBCs over time in URE het Msh2 −/− mice and found that the WBCs rapidly increased shortly before death (Fig. 1g) , indicating the presence of an acute disease. Aberrant myeloid blasts were present in the peripheral blood, bone marrow and spleen of mice, stained positive for the myeloid marker myeloperoxidase and disrupted the tissue architecture of the spleen, liver and bone marrow ( Fig. 1h and Supplementary Fig.  1f-h ). Cytogenetic examination of AML cells showed evidence for clonality (Supplementary Table 1 ).
The bone marrow and spleens of URE het Msh2 −/− mice with AML showed an expanded cKit + CD8a − CD4 − B220 − cell population that also expressed high levels of CD44 (Supplementary Fig. 1i-k) . Further analysis revealed variations in disease phenotype (Fig. 1i) . In 17% of mice with AML (termed ' AML (immature)'), the aberrant populations appeared morphologically immature ( Supplementary  Fig. 1l) , and the majority of cKit + cells lacked expression of the mature myeloid marker CD11b (Supplementary Fig. 1j) . 33% of the URE het Msh2 −/− mice with AML (termed ' AML (mature)') displayed aberrant cKit + CD44 + CD8a − CD4 − B220 − cells coexpressing CD11b (Supplementary Fig. 1j , third panel from the top), with blasts in these mice resembling more mature metamyelocyte-like neutrophils with ring-shaped nuclei (Supplementary Fig. 1l) . 50% of the URE het Msh2 −/− mice with AML (termed ' AML and ALL (mixed lineage)') harbored an aberrant myeloid cKit + CD44 + CD8a − CD4 − B220 − population and a separate, expanded CD8a + and/or CD4 + morphologically immature cell population within the hematopoietic organs ( Supplementary Fig. 1i ,j, bottom panels, and Supplementary  Fig. 1m-o npg or T cell lymphoma had a significantly faster rate of disease progression as compared to mice that developed AML alone (P < 0.001, logrank test) (Fig. 1j) . These data show that minimal reduction of PU. (Fig. 2a) . However, URE het Msh2 −/− cells of either AML subtype showed greater clonogenic capacity in the second to fifth plating and continued to give rise to aberrant blast-like colonies after the WT colony-initiating cells were exhausted. The number of myeloid colonies with normal morphology derived from immature or mature AML cells was found to be reduced in the first plating ( Fig. 2a) . URE het Msh2 −/− -derived aberrant colonies were comprised of differentiation-impaired myeloid cells with blast morphology and became the sole colony type after the initial cell plating ( Fig. 2a-c) . Cells isolated from the blast colonies maintained the same immunophenotype as the primary AML bulk cell population ( Fig. 2d and Supplementary Fig. 1i-k) . Next, we transplanted purified cKit + Lymph − cells and stem cell-enriched LSK populations into immunocompromised NOD-SCID IL2Rγ-null (NOG) mice. Recipient animals displayed a massive expansion of a donor-derived bulk tumor population with the same phenotype as that observed in the primary tumors ( Fig. 2e-h and Supplementary  Fig. 2a-d ). All recipients died of AML within 3-11 weeks, demonstrating that the disease is transplantable from the stem cellcontaining cell compartment ( Fig. 2g and Supplementary Fig. 2d ).
Gene expression analysis of leukemia-initiating cKit + Lymph − cells from URE het Msh2 −/− mice revealed alterations that substantially affected several cellular networks. Comparison with cKit + Lymph − cells from age-matched healthy URE + Msh2 +/+ mice identified 587 annotated, differentially expressed genes (Supplementary Table 2) , which separated URE het Msh2 −/− AML cells from WT cells in a hierarchical cluster analysis (Fig. 2i) . Pathway analysis showed that differentially expressed genes were enriched for molecules involved in several key cellular processes ( Fig. 2j and Supplementary Fig. 2e ).
Role for Irf8 downregulation in AML induction
Among the differentially expressed genes found in cKit + Lymph − cells from URE het Msh2 −/− AML, we identified Irf8 (also known as ICSBP) to be significantly reduced compared to cells from age-matched URE + Msh2 +/+ (WT) controls (P = 0.025, Student's t-test) (Fig. 3a) . As Irf8 cooperatively regulates the expression of target genes together with PU.1 (refs. 30-32), we examined whether a subset of the deregulated genes in URE het Msh2 −/− AML are common targets of PU.1 and Irf8. Using published chromatin immunoprecipitation and sequencing (ChIP-seq) data sets, we identified genes with PU.1 or with combined PU.1 and Irf8 occupancy within their promoter regions that were also differentially expressed in URE het Msh2 −/− AML ( Supplementary  Tables 3 and 4) . Both subsets of genes showed a significant (-log (P value) > 1.3) enrichment of genes involved in AML-relevant pathways ( Fig. 3b and Supplementary Fig. 3a) . Motif enrichment analysis designated a PU.1-IRF composite DNA-binding motif containing a PU-box and an adjacent IRF consensus site as the top enriched motif (Fig. 3c) . Intersection of the genes occupied by PU.1 and Irf8 in their promoter regions with the differentially expressed genes in URE het Msh2 −/− AML cells (as compared to those in URE +/+ Msh2 +/+ cells) showed reduced expression of several co-occupied genes (Supplementary Fig. 3b ). We next tested whether these could be rescued by Irf8 restoration using a retroviral vector system containing a GFP reporter. Compared to the empty vector control, transduction with a retrovirus encoding Irf8 led to restoration of Irf8 protein levels (Fig. 3d) and, concomitantly, a significant increase (P < 0.05, Student's t-test) in the expression of several putative PU.1-Irf8 target genes, including Fam132a, Rnf13, Osbpl3 and previously established PU.1-Irf8 co-regulated targets Etv3, Nf1 and Emr1 in URE het Msh2 −/− AML cells ( Fig. 3e and  Supplementary Fig. 3c,d ). Irf8 expression restoration also induced myeloid differentiation of URE het Msh2 −/− AML cells as evidenced by morphological analysis and immunophenotyping (Fig. 3f,g ). Furthermore, we observed induction of apoptosis in leukemic cells upon rescue of Irf8 expression (P < 0.05, Student's t-test) (Fig. 3h) . Restoration of Irf8 expression also led to significantly impaired selfrenewal of URE het Msh2 −/− AML cells (P < 0.05, Student's t-test) and a progressive loss of colony-initiating cKit-expressing cells in serial replating assays ( Fig. 3i and Supplementary Fig. 3e ). Mice injected with Irf8-rescued (GFP + ) URE het Msh2 −/− AML cells survived significantly longer than mice transplanted with GFP + URE het Msh2 −/− AML cells infected with an empty vector control (P < 0.001, log-rank test; Fig. 3j ). Competitive transplantation of a mix of Irf8-restored (GFP + ) and nonrestored (GFP − ) URE het Msh2 −/− AML cells demonstrated that low Irf8 levels were critical to conferring growth advantage in vivo, as URE het Msh2 −/− AML cells with restored Irf8 levels were outcompeted by GFP − AML cells in the recipients' bone marrow (BM) and spleen (SP); this observation was not made with the empty vector control (Fig. 3j) . The rescue of PU.1 expression led to similar differentiation and apoptosis-inducing effects as those observed with the rescue of Irf8 in the mouse AML cells (Supplementary Fig. 3f-h) . Together, these data show that reduced expression of Irf8 contributes to the myeloid differentiation block, impaired apoptosis, in vitro self-renewal and the competitive growth advantage of leukemic cells in URE het Msh2 −/− AML.
Minimal PU.1 expression reduction induces a preleukemic state Irf8 was not decreased at the preleukemic stage (Fig. 4a) . In contrast, PU.1 expression, although minimally reduced, did not change upon progression to AML (Fig. 4a) . FACS analysis of phenotypically defined HSC and lymphoid-myeloid multipotent progenitor cells (LMPP) (Supplementary Fig. 4a) Fig. 4 b,c and Supplementary  Fig. 4b ). We next assessed multilineage reconstitution by highly purified, phenotypic lineage-unbiased HSCs or myeloid-biased HSCs from URE het Msh2 +/+ animals; reconstitution with either population resulted in a marked increase in donor-derived myeloid cells in the peripheral blood of recipient animals versus animals transplanted with WT HSCs (Fig. 4d and Supplementary Fig. 4c) . In vivo BrdU labeling revealed an increase in cycling cells within the phenotypic myeloidbiased HSC population in URE het mice (Supplementary Fig. 4d ). These results demonstrate that minimal PU.1 expression reduction npg is sufficient to induce functional alterations in the immature hematopoietic cell compartment. HSC-enriched cell populations derived from preleukemic URE het Msh2 −/− mice (using URE + Msh2 −/− mice as controls) had an extended self-renewal capacity with colony initiation beyond the fourth plating (Fig. 4e) . Using serial bone marrow aspirations and peripheral blood sampling of preleukemic URE het Msh2 −/− mice, we observed a progressive increase in the number of immature myeloid cells (cKit + CD11b −/lo Lymph − ) along with a gradual decrease in the number of mature myeloid cells (Gr-1 high CD11b + Lymph − ) (Fig. 4f,g and Supplementary Fig. 4e,f) as well as expansion of the phenotypic HSC-MPP compartments (Supplementary Fig. 4g ). Furthermore, in preleukemic mice, we detected cells with dysplastic morphological features, including pseudo-Pelger-Huet cells, megablastoid erythropoiesis, eosinophilic hypergranulation and a mild increase in numbers of promyelocytes and neutrophilic myelocytes (Fig. 4h) . Longitudinal complete blood cell count (CBC) analysis showed normal numbers of total white blood cells and red blood cells and slightly reduced platelet numbers (Fig. 1f) in the early preleukemic phase (12-30 weeks before overt AML), a slight but significant reduction of cells in all three lineages during the late preleukemic phase (4-6 weeks before overt AML) and an up to 25-fold increase in white blood cells accompanied by a progressive reduction of red blood cells and platelets in the leukemic stage (Fig. 4i) Table 5 ) affecting pathways that were also found significantly deregulated in human myelodysplastic syndrome (MDS) (P > 1.3 × 10 −4 ; Fig. 4j and Supplementary Table 6 ). These observations demonstrate that minimally impaired PU.1 induces myeloid-biased mouse HSPCs and, in the context of Msh2 deficiency, increases self-renewal and leads to the development of a preleukemic state that resembles the cellular and molecular features of human myelodysplasia, a preleukemic disease.
Similarities between mouse URE het Msh2 −/− -derived AML and human AML Comparative pathway analysis of differentially expressed genes in leukemic URE het Msh2 −/− cKit + Lymph − cells (relative to age-matched WT controls) identified significantly dysregulated pathways (P > 1.3 × 10 −4 ) that were shared with human AML (derived by comparing persons with AML versus healthy individuals) ( Fig. 5a and Supplementary Table 7) . We next evaluated whether molecular alterations seen in mouse URE het Msh2 −/− -induced leukemogenesis were observed during the process of myeloid transformation in humans. As human AML development is highly age dependent 35 , we first tested whether changes in PU.1 expression occur during human aging. Our analyses revealed slightly but significantly decreased expression levels of PU.1 in highly purified HSC from healthy >65-year-old donors when compared to levels in HSCs from young, 20-to 35-year-old donors (P < 0.05; Fig. 5b ). We next assessed whether the reduction in PU.1 expression correlates with the expression of its transcriptional target genes in human AML. We divided individuals from two published gene expression studies into two subgroups: 'PU.1 lower' npg and 'PU.1 higher' individuals ( Fig. 5c and Supplementary Fig. 5a ). We determined the differential gene expression profiles between the two groups and identified 325 probe IDs, which corresponded to 219 unique annotated genes, with expression changes that were also found to be differentially expressed in mouse AML (versus age-matched WT controls; Fig. 5d and Supplementary Fig. 5b ). Among the differentially expressed genes we found a significant enrichment of genes harboring the PU.1-binding motif in their promoters (P < 0.05, Fisher's exact t-test; Supplementary Fig. 5c ), suggesting that the reduction in PU.1 expression has an impact on the expression of its target genes.
To test the hypothesis that the molecular alterations seen in our mouse AML model show more similarities to human AML with lower PU.1 expression than to human AML with higher PU.1 expression, we used two different approaches. We performed comparative gene set enrichment analysis (GSEA) and found that dysregulated gene expression programs in the 'PU.1 lower' group of individuals with AML enriched for 1,223 gene sets that were also concordantly altered in mice with AML, whereas GSEA between the 'PU.1 higher' group of people with AML and mice with AML revealed only 464 shared gene sets (Supplementary Fig. 5d ). Using a second analysis strategy we directly tested whether genes that were differentially regulated in mouse AML are dysregulated in human AML that is associated with lower or higher PU.1 expression. The set of genes aberrantly expressed in mouse AML showed enrichment in the group of aberrantly expressed genes found in the 'PU.1 lower' group of people with AML, whereas they were not enriched in the 'PU.1 higher' group ( Supplementary Fig. 5e ). Interestingly, among the genes correlated with 'PU.1 higher' or 'PU.1 lower' expression status in AML patients, we also found IRF8 (Fig. 5e and Supplementary Fig. 5f ). We found no significant IRF8 expression change during aging (Fig. 5f ) or in patients with lower risk MDS (Fig. 5g) ; yet, we detected lower IRF8 expression in advanced stage MDS patients (with refractory anemia and an excess of blasts (RAEB)), whose disease has a higher propensity for progressing to AML (Fig. 5g) . Consistent with this observation, MDS patients with lower IRF8 expression had a significantly worse overall probability of survival (P = 0.0144) than patients with higher IRF8 expression (Supplementary Fig. 5g ). AML patients with lower PU.1 expression showed a significant (P < 0.001) hypermethylation of the IRF8 promoter (Fig. 5h) . Lastly, we compared expression changes found in URE het Msh2 −/− leukemia-initiating cells with differential gene expression in human leukemic stem cells (LSCs) versus healthy HSCs. Notably, although we detected a significantly positive correlation between PU.1 and IRF8 expression in LSCs from two independent studies (Fig. 5i) , PU.1 and IRF8 expression patterns in healthy HSCs did not show a similar correlation (Fig. 5j) . Together, these data show a marked molecular resemblance between mouse URE het Msh2 −/− -derived AML and human acute myeloid leukemia pathogenesis. When we restored IRF8 expression in human AML cell lines showing IRF8 'lower' (such as Kasumi-3 or ML-2 cells) or IRF8 'higher' (such as Nomo-1 or Molm14 cells) expression patterns (Supplementary Fig. 5h ), we found that increased IRF8 levels led to induction of differentiation in all four of the IRF8 'lower' cell lines and apoptosis in two of these AML cell lines, whereas ectopic expression of IRF8 in the IRF8 'higher' AML cell lines neither induced differentiation nor apoptosis (Supplementary Fig. 5i ).
DISCUSSION
Modest impairment of PU.1 activity or expression is common in human AML pathogenesis, yet mouse models have failed to demonstrate a functional relevance for minimal dosage alterations of this key hematopoietic regulator in AML. Here we provide genetic evidence that minimal inhibition of PU.1 can be a founding event in leukemogenesis.
Our data reveal that a 35% reduction in PU.1 expression introduces a myeloid bias in multipotent mouse HSPCs. Our phenotypic marker analysis suggested there was an expanded myeloid-biased HSC population in mice with reduced PU.1. However, cell cycle studies showed that these cells were less quiescent than their wild-type counterparts, in line with a previous report 36 . Adoptive cell transfer experiments showed that, although myeloid biased, these cells were still capable of multilineage reconstitution. Thus, even though cell surface markers define this population as myeloid-biased HSCs, the phenotypic characteristics are more consistent with an early multipotent progenitor. Notably, these myeloid lineage-biased multipotent cells did not give rise to overt myeloid leukemia, which is in line with previous observations from PU.1-haploinsufficient mice 37, 38 . Furthermore, we found minimally reduced PU.1 expression levels in aged, but otherwise healthy, human HSCs, which have also been shown to harbor a myeloid lineage bias 39, 40 .
Molecularly, PU.1 exerts many of its functions by binding highly specific DNA sequence motifs, often in concert with other transcription factors. Among the genes whose expression was significantly reduced in immature myeloid cells from URE het Msh2 −/− mice with AML, we identified Irf8, a PU.1 cofactor [30] [31] [32] that is frequently lost or impaired in human myeloid leukemia 30, 41 . Irf8-deficient mice show dysfunctional granulocytic-monocytic lineage determination and develop a myeloproliferative neoplasm 42 . In human hematopoietic stem and progenitor cells, monocytes and macrophages, PU.1-IRF8 consensus DNA-binding motifs discriminate PU.1 consensus sites with actual PU.1 occupancy from those that are not bound by the transcription factor 43 . We found that restoration of Irf8 expression in leukemic URE het Msh2 −/− cells rescued the impaired expression of genes harboring PU.1-IRF consensus-binding sites, led to the loss of aberrant self-renewal, promoted myeloid differentiation and induced apoptosis, which demonstrates that Irf8 impairment functionally cooperates with lower PU.1 expression in our model. IRF8 downregulation has also been shown to cause resistance to apoptosis and to be associated with disease progression in human leukemia 44 . Our results provide evidence that minimal PU.1 reduction cooperates with IRF8 impairment in human leukemogenesis: (i) patients with myelodysplastic syndrome (MDS) with a higher risk for progression to AML had lower IRF8 levels, suggesting that inactivation of IRF8 promotes leukemogenesis, (ii) lower IRF8 expression was detected specifically in AML patients with lower PU.1 levels, (iii) restoration of IRF8 expression induced differentiation in 'IRF8 low' AML cells, and (iv) a positive correlation of PU.1 and IRF8 expression was found in human leukemia stem cells, but not in healthy HSCs.
Aging hematopoietic stem cells progressively accumulate mutations and molecular alterations which can impair cellular function, give rise to preleukemic stem cells and initiate age-associated myeloid malignancies 45, 46 . By modeling the accumulation of small DNA lesions during the aging process by using an Msh2-deficient mouse background, we found that a minimal reduction in PU.1 expression triggered significant cellular and molecular alterations that were consistent with MDS, a preleukemic disorder that frequently progresses to AML 47 . Compound mutant URE het Msh2 −/− mice also frequently developed AML that, as in human AML, showed considerable phenotype heterogeneity. This variability is most likely due to differences in acquired genetic and epigenetic alterations in Msh2-deficient cells and further supports a role for PU.1-dependent stem cell fate npg dysregulation as an early preleukemic event during leukemogenesis. Recent studies in patients with AML have confirmed the functional importance and clinical significance of preleukemic stem cell populations as the cellular origin of leukemia-initiating cells in human disease 7, 27, 47, 48 . However, our functional and mechanistic knowledge of preleukemic stem cells and their progression is still very limited. Our study reveals a mechanism of leukemic transformation that is mediated by the minimal inhibition of a key transcriptional regulator of hematopoiesis, PU.1, which alters hematopoietic stem cell fate and sensitizes them to further malignant transformation.
Genetic models have demonstrated that alteration of enhancer function can cause hematologic diseases 49, 50 . Very recently, AML has also emerged as such an 'enhanceropathy' 51 . Our study provides further proof that even the heterozygous disruption of critical cis-regulatory regions can be potent drivers of malignant transformation. It is possible that other key transcriptional regulators that exhibit small changes in expression levels play critical roles in malignant transformation, particularly in the early stages of tumorigenesis, and thus deserve our attention in the future.
METHODS
Methods and any associated references are available in the online version of the paper.
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